EGFR and lung carcinoma: This is consistent with Li’s research [23] that patients with lung cancer with EGFR mutations are more likely to develop brain metastases than patients with EGFR wild-type (OR = 1.99, 95% CI: 1.59–2.48, P = 0.000).